Company intelligence / Profile preview

Iconovo

Lund, Skåne County, Swedeniconovo.se ↗

Ownership: Private
Development stage: Commercial

Overview

Iconovo develops and licenses innovative dry powder inhaler devices and formulations to pharmaceutical partners globally. Their platforms enable both generic versions of established drugs and the development of new inhaled medicines. The company's business model centers on outlicensing its patented devices to pharma partners who then develop or commercialize products using these technologies.

Therapeutic areas: Pulmonology
Modalities: DeviceSmall molecule (as inhaled generics and new drugs)Biologic (potentially, as platform is modality agnostic for inhaled forms)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

inhaled oxytocin

Phase 1

Indications: Postpartum hemorrhage

Partnerships

AffilogicENA Respiratory Pty LtdLonzaStevanato GroupKiox PharmaMonash University

Beyond the preview

Go deeper on Iconovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iconovo.

Explore the full profile